The renin-angiotensin-aldosterone system (RAAS) has been identified as a major contributor to the development of cardiac hypertrophy and the subsequent transition to heart failure. G protein-coupled receptors agonists such as angiotensin II (Ang II), endothelin-1 (ET-1) and phenylephrine (PE) have been implicated in hypertrophic responses in ventricular myocytes through the activation of several families of MAP kinases. In this study we examined the effect of candesartan, an Ang II type 1-(AT 1 )-receptor antagonist, on cardiac hypertrophy by using cultured neonatal rat cardiomyocytes. Stimulation with Ang II (100 nM), ET-1 (100 nM) or PE (1 µM) induced marked increases in [ 3 H]Leucine incorporation (≥ 50%), compatible with enhanced protein synthesis. The addition of candesartan abrogated the increase in [ 3 H]Leucine incorporation in response not only to Ang II but also to ET-1 and PE. To elucidate the mechanisms involved in this antihypertrophic effect of candesartan, we studied the activation of p38-MAPK, extracellular signal-regulated kinases (ERK 1/2 ) and stress-activated protein kinases (SAPKs). Ang II, ET-1 and PE increased the phosphorylation levels of ERK 1/2 , p54 SAPK and p46 SAPK and p38 in a time-dependent manner. This activation was completely blocked in the case of Ang II by pretreatment with candesartan. ET-1-induced activation of ERKs, SAPKs and p38 was also partially, but significantly, reduced by candesartan. PE-induced activation of SAPKs, but not ERKs and p38, was also reduced by candesartan. These results suggest that the hypertrophic response to ET-1 and PE, along with Ang II, is dependent upon a functioning AT 1 -receptor and may be mediated by AT 1 activation of the MAP kinases.
Introduction
Cardiac hypertrophy due to valvular or hypertensive heart disease is one of the most common causes of congestive heart failure worldwide. Despite this, the signal transduction mechanisms mediating the complex response of cardiomyocytes in vivo to hypertrophic stimuli and the progression from hypertrophy to heart failure are poorly understood. Many lines of evidence have suggested that a variety of mechanical, haemodynamic and hormonal/growth factor stimuli play a pivotal role in developing cardiac hypertrophy. In response, the heart adapts to increased demands for cardiac work by induction of the immediateearly genes (such as c-fos, c-myc, c-jun, and erg-1) which may play a role in the early phases of the hypertrophic response followed by transcriptional reactivation of specific embryonic genes (such as skeletal α-actin, β-myosin heavy chain and atrial natriuretic factor) and increases in protein synthesis. 1, 2 Although initially beneficial, prolonged cardiac hypertrophy can be maladaptive and eventually leads to decompensation, heart failure and often to sudden death. 3 The identification and characterisation of hypertrophic signalling pathways have been the focus of intense investigation in recent years. Studies employing pharmacological inhibitors or transient transfection of cardiomyocytes in vitro with constitutively-active components of three different mitogen-activated protein kinase (MAPK) cascades have suggested roles for these cascades in the hypertrophic response.The three MAPK cascades which have been implicated are those culminating in the activation of the extracellular signal-regulated kinases (ERK 1 and ERK 2 ), the stress-activated protein kinases (SAPKs, also known as c-jun N-terminal kinases or JNKs), and another family of stress-activated kinases which includes p38 and related kinases. 4, 5 Calcineurin, a calcium/calmodulin-dependent phosphatase, and the transcription factor nuclear factor of activated T-cells 3 (NF-AT3), have been shown to be implicated in the regulation and control of cardiomyocyte hypertrophy. 6 Recent evidence points to a certain degree of cross-talk between the different MAPK pathways and between MAPK pathways and calcineurin. 7 It is now well established that vasoactive agents such as Ang II, endothelin-1 (ET-1) and phenylephrine (PE) are potent stimulators of the hypertrophic response in cardiomyocytes in culture, and also likely play a pivotal role in vivo. 2, 8, 9 These agonists can directly activate the hypertrophic response via interactions with serpentine receptors coupled to heterotrimeric G proteins of the Gq family; namely the Ang II type 1(AT 1 )-receptor, 10 ET A receptor 11 and α 1A -adrenergic receptor. 12 Moreover, it has been reported that mechanical stress stimulates the release of Ang II 13 and ET-1 9 from cardiac myocytes which, in turn, in an autocrine/paracrine manner induce cardiomyocyte hypertrophy. Surprisingly, these agonists were also shown to activate the three MAPK cascades (including ERKs, JNKs and p38) that mediate signal transduction, leading to aspects of hypertrophy. 14 Inhibition of Ang II and ET-1 signalling pathways, through AT 1 -receptor and ET A receptor blockade, abrogates the hypertrophic response of cardiomyocytes in vitro and in vivo. Pretreatment of neonatal cardiomyocytes with BQ123, a selective ET A antagonist, completely blocked ET-1induced activation of Raf-1 kinase and MAP kinases and attenuated the stretch-induced increase in phenylalanine incorporation into cells. 9 Ito et al. demonstrated that ET A receptor blockade prevented the development of cardiac hypertrophy induced by aortic banding. 15 On the other hand, the use of Ang II AT 1 -receptor blockers (ARBs) has lent support for a role of Ang II and AT 1 -receptors in the development of hypertrophy and subsequent transition to heart failure. Several ARBs are currently available and they all share a common mechanism of action: they selectively block AT 1 -receptors which are responsible for most, if not all, of the actions of Ang II in the cardiovascular system. 16 Despite their AT 1 -receptor specificity, these ARBs differ pharmacologically in terms of their affinity for the AT 1 -receptor and the duration of their receptor blockade. 17 Several studies have revealed that ARBs effectively reduce blood pressure in humans and in a variety of genetic and experimental models of hypertension. 17, 18 Recent clinical results suggest that ARBs may also be beneficial in reducing some aspects of cardiac and vascular remodelling associated with cardiovascular disease and in treating congestive heart failure. [19] [20] [21] In a model of left ventricular (LV) myocardial infarction (MI) caused by coronary artery ligation in rats, ARBs largely prevented the development of LV hypertrophy. 22 Moreover, in spontaneously hypertensive rats (SHR), administration of ARBs, at an age when hypertrophy is well established, helped to prevent further LV wall thickening and led to regression of hypertrophy. 23 Candesartan, a novel generation of ARBs, is a non-peptide highly specific Ang II AT 1 -receptor antagonist, with no apparent effect on Ang II binding to Ang II type 2 (AT 2 )-receptors. 18, 24 In vitro studies have shown that candesartan not only exhibits higher affinity for the AT 1 -receptor compared with other ARBs, but also acts as an insurmountable AT 1 -receptor antagonist, in that complete suppression of the maximal response to Ang II can be achieved. This insurmountable antagonism reflects the tight binding of candesartan to, and its slow dissociation from, AT 1 -receptors. 16 These characteristics are thought to contribute to the potent and long-lasting antihypertensive effects of candesartan in clinical trials and in several animal models of hypertension. 17, 18 Other studies have shown that candesartan has the beneficial potential to inhibit cardiac hypertrophy and to improve signs and symptoms of congestive heart failure. 17, 25, 26 The objective of the present study was to determine whether candesartan is able to attenuate cardiomyocyte hypertrophy induced by various hypertrophic stimuli, i.e. Ang II, ET-1 and PE. This aim was accomplished by using cultured neonatal rat cardiomyocytes as an experimental model and assessing markers of hypertrophic responses such as MAP kinases (ERK, SAPK and p38) activation, ANF expression and increases in protein synthesis. Our findings suggest that candesartan is effective, not only at blocking Ang IIinduced hypertrophy, but also hypertrophy induced by other important hormonal stimuli such as ET-1 and PE in isolated cardiomyocytes.
Materials and methods
Isolation and culture of neonatal rat cardiomyocytes Spontaneously beating cardiomyocytes were prepared from 1-to 2-day-old Sprague-Dawley rat pups using the Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corp.) and cultured overnight in F-10 medium (GIBCO BRL) in the presence of 5% FCS and 10% horse serum, 100 U/ml penicillin/streptomycin and 2 mM L-glutamine.The medium was then removed and cardiomyocytes were serum-starved (F-10 plus 0.1% FCS) for 36 hours before stimulation with Ang II (100 nM), Endothelin-1 (100 nM) or phenylephrine (1 µM) (Sigma) in the presence or absence of candesartan (AstraZeneca) for the indicated times.
Measurements of protein synthesis
Protein synthesis rates were determined using [ 3 H]-Leucine incorporation. Cardiomyocytes were prepared as described above and plated in triplicate 12-well plates. After serum-starving for 36 hours, the cells were stimulated for 36 hours in serum-free F-10 and then incubated with 1 µCi/ml [ 3 H]-Leucine (NEN Life Science Products) for the last 7 hours. The cells were washed twice with ice-cold 1X PBS and fixed on ice with 10% cold trichloroacetic acid (TCA) for 60 minutes. After washing twice with 6% cold TCA and once with water, the precipitates were air-dried and then solubilised in 0.5 N NaOH. [ 3 H]-Leucine incorporation was measured by scintillation counting. S155
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Figure 1 3 H-Leucine Incorporation into cardiomyocytes.
Neonatal cardiomyocytes in triplicate wells of 12-well plates were serum-starved then stimulated for 36 hours by Ang II, ET-1 and PE in the presence or absence of candesartan (10 -7 M). 3 H-Leucine (1 µCi/ml) was added 7 hours before harvesting.The total 3 H-Leucine incorporated was determined by liquid scintillation counting.
H-leucine incorporation (cpm/5x10 -5 cells)
Journal of the Renin-Angiotensin-Aldosterone System
(Including other peptidergic systems) . Films from at least three independent experiments were scanned and densitometry analysis was performed using NIH Image.
Results
Candesartan abrogation of agonist-induced increase in 3 H-Leucine incorporation into myocytes
We determined the hypertrophic effect of Ang II, ET-1 and PE using 3 H-Leucine incorporation into myocytes as a marker of protein synthesis. Stimulation of cultured neonatal rat cardiac myocytes with Ang II (100 nM), ET-1 (100 nM) or PE (1 µM) for 36 hours caused a marked increase in leucine incorporation, compatible with enhanced protein synthesis ( Figure 1 ). Pretreatment with candesartan (100 nM for 45 minutes) completely abolished (to control levels) this observed increase in March 2001 Volume 2 Supplement 1 S157 3 H-Leucine incorporation into cardiomyocytes exposed, not only to Ang II, but also to ET-1 and PE (Figure 1 ). Candesartan, in the absence of any stimulation, had no effect on amino acid incorporation.
MAP kinases activation and effects of candesartan
MAP kinases are key molecules in intracellular signal transduction and play an essential role in cellular proliferation and differentiation. Moreover, MAP kinases activities are sensitive and quantitative markers for hypertrophic responses in cardiac myocytes.To elucidate the mechanisms involved in the attenuation of hypertrophy by candesartan as measured by 3 H-Leucine incorporation, we studied the activation of ERK, SAPK and p38. Cultured cardiomyocytes were serum-starved for a period of 36 hours, then exposed to Ang II (100 nM), ET-1 (100 nM) or PE (1 µM) for 10 or 30 minutes in the presence or absence of 100 nM candesartan. Sorbitol (100 µM or 500 µM) was used as a positive control stimulator. Following stimulation, myocytes were harvested in lysis buffer containing various proteases and phosphatases inhibitors and frozen immediately in liquid nitrogen. Equal amounts of protein were loaded on SDS gels and analysed by immunoblotting according to standard methods. Phosphorylation levels (i.e., activation) of all MAP kinases were detected using specific phosphoantibodies. Total protein contents of the corresponding MAP kinases were also determined after stripping the phospho-blots.
Effects of candesartan on Ang II-induced phosphorylation of ERK, SAPK and p38
Ang II caused an increase in MAPKs activity, with an increased phosphorylation of ERK 1 and ERK 2 , p54 SAPK and p46 SAPK and p38 in a time-dependent manner (Figure 2A , Phospho panels). Candesartan significantly decreased the phosphorylation, below base-line levels, of ERK 1 and ERK 2 and p54 SAPK and p46 SAPK ( Table 1 ). The activation of p38, however, was only partially blocked by candesartan ( Figure 2A , Table 1 ). Blots in Figure 2A (Total panels) also show that the same amount of total proteins was present in each sample, suggesting that the changes in the phosphorylation levels are due to the activation of the MAP kinases.
Effects of candesartan on ET-1-induced phosphorylation of ERK, SAPK and p38
Like Ang II, ET-1 caused an increase in MAPKs activity, with an increased phosphorylation of ERK 1 and ERK 2 , p54 SAPK and p46 SAPK and p38 compared with non-stimulated samples ( Figure 3A , Phospho panels, Table 1 ).
Candesartan partially decreased the phosphorylation of phospho-ERK 1/2 and phospho-p38 but completely abolished the activation of p54 SAPK and p46 SAPK ( Figure 3A , Table 1 ). Figure 4 shows the stimulation of MAP kinases by PE. Compared with control samples, PE induced a significant increase in phosphorylation levels of the three MAP kinases. Pretreatment with candesartan significantly blocked phospho-p54 SAPK and phospho-p46 SAPK but had almost no effect on ERK 1/2 and p38 (Table 1, Figure 4A , Phospho panels). Figure 4A also shows equal loading of total proteins (Total panels).
Effects of candesartan on PE-induced phosphorylation of ERK, SAPK and p38
Effects of candesartan on sorbitol-induced phosphorylation of ERK, SAPK and p38
To validate the above-observed effects of candesartan on the phosphorylation activities of the PAPER MAP kinases, we examined the effect of candesartan in cardiomyocytes exposed to sorbitol, which is a powerful hypertrophic agonist. Sorbitol (500 µM) caused marked increases in phosphorylation levels of all MAP kinases investigated, ERK 1 and ERK 2 , p54 SAPK and p46 SAPK and p38 ( Figure 5 ; see also Figure 2A , 3A and 4A lanes marked SB). Lower concentrations of sorbitol (100 µM) produced the same changes (not shown). This increase in MAP kinases phosphorylation was unaffected by candesartan. Candesartan alone had no inhibitory effects on MAP kinase activation ( Figure 5 ). Taken together, the above results show that candesartan is effective in altering the phosphorylation activities of MAP kinases, particularly p54 SAPK and p46 SAPK , not only in response to Ang II stimulation, but also to ET-1 and PE.This effect is specific to Ang II, ET-1 and PE stimulation, since candesartan alone or in the presence of sorbitol had no apparent effect on the protein kinase cascades.
Discussion
The cardiac renin-angiotensin system (RAS) has been identified as a major contributor to the development of hypertrophy and congestive heart failure. The primary effector molecule of the RAS is Ang II. Although Ang II binds to and activates two distinct angiotensin receptors (AT 1 and AT 2 ) most of its important biological actions are medi-ated through AT 1 -receptors. Therefore, the blockade of the AT 1 -receptor is thought to be of considerable therapeutic benefit.To this end, several Ang II receptor blockers (ARBs) have been introduced. They selectively block the RAS at the target-organ AT 1 -receptor level and thereby block the effects of Ang II that contribute to hypertension and cardiac remodelling. By blocking the AT 1 -receptor, more Ang II is available to activate the AT 2 -receptor, which mediates potentially beneficial antiproliferative and vasodilatory actions.
Candesartan has been shown to inhibit cardiac hypertrophy and improve signs and symptoms of congestive heart failure. 17, 26, 27 We hypothesised that candesartan will inhibit the hypertrophic responses induced in cardiomyocytes that have been exposed to various hypertrophy-promoting factors. In the present study, we have demonstrated that candesartan was effective in completely blocking hypertrophy in neonatal cardiomyocytes induced by ET-1 and PE, along with Ang II, as measured by 3 [H]-Leucine incorporation.This observation is consistent with findings by other laboratories.Yamazaki et al. 28 showed that candesartan significantly suppressed the increase in amino acid incorporation into myocytes following Ang II or stretch stimulation. Sadoshima et al. 13 also reported that increases in phenylalanine incorporation and c-fos gene expression were completely blocked by the Ang II receptor antagonist, saralasin, and the specific AT 1 -receptor antagonist, losartan. To elucidate the mechanisms involved in this antihypertrophic effect of candesartan, we have determined the activities of cardiac p38-MAPK, extracellular signal-regulated kinases (ERK 1/2 ) and stress-activated protein kinases (SAPKs). As expected, stimulation of myocytes with Ang II, ET-1 or PE strongly activated the three MAP kinases compared with baseline levels. This activation was differentially attenuated by candesartan, depending on the type of stimulus. Phosphorylation of p54 SAPK and p46 SAPK was completely suppressed by candesartan following stimulation by Ang II, ET-1 and PE. However, p38-MAPK phosphorylation was only partially affected following pretreatment with candesartan. ERK phosphorylation activities were also partially suppressed by candesartan when stimulated with ET-1 and PE but completely abrogated following Ang II induction. These data suggest that the hypertrophic response to ET-1 and PE, along with Ang II, is dependent upon a functioning AT 1 -receptor and may be mediated by AT 1 -receptor activation of the ERKs and SAPKs.These findings are, to some extent, similar to the findings of Izumi et al. 29 on the effect of losartan on the activities of these MAPKs in stroke-prone SHRs. These investigators were able to show in vivo that the prevention of cardiac hypertrophy by losartan was associated with a remarkable reduction in SAPK (JNK) activities, and to a lesser degree ERK activities. 29 However, it is not clear how ET-1 and PE affect the activities of the MAPKs following AT 1 -receptor blockade with candesartan. One possible explanation is that there is cross-talk between the different surface receptors and their coupled molecules. 30 Candesartan inhibition of MAPKS following ET-1 and PE stimulation is probably due to the inhibition of the complex growth-promoting pathways downstream of the Gq protein.There is also the possibility that the effect of ET-1 and PE can be mediated through the release of Ang II from the myocytes, which in turn activates AT 1 -receptors. Yamazaki et al., 9 on the other hand, reported that candesartan had no effects on ET-1-induced ERK 1/2 activities, results which conflict with our own findings. Despite the fact that the reason is not clear at present, the decrease in phosphorylation levels of ERK 1/2 might be due to dephosphorylation of these MAP kinases by phosphatases, activated during cardiomyocytes stimulation. 
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Although the present study did not permit us to elucidate the mechanism and significance of the abrogation of MAP kinases activities by candesartan following ET-1 and PE stimulation, experiments are underway to determine that. Worthy of note are the observed beneficial effects in animal models and humans of angiotensin-converting enzyme (ACE) inhibitors on cardiac remodelling. 31 Although they produce the same degree of target-organ protection, ACE inhibitors (ACE-I) and ARBs modulate the cardiac RAS by different mechanisms. Generally, ACE-I have the ability to reduce the formation of Ang II and increase bradykinin levels. 32 However, these agents do not block Ang II formation via non-ACEmediated tissue pathways. ARBs on the other hand, tend to block the binding of Ang II to its receptor (AT 1 -receptor), regardless of whether it is produced systemically in the circulation or locally via ACE or non-ACE-dependent cascades. ARBs also block the Ang II-induced feedback modulation of renin release, resulting in an increase in Ang II levels. In blocking AT 1 -receptors, greater levels of Ang II are available to bind to and activate AT 2 -receptors, which are thought to mediate several potentially beneficial cardiovascular effects. 33 From this mechanistic perspective, and by virtue of their ability to selectively and completely block the effects of Ang II, ARBs would appear to have advantages over ACE-I in reducing cardiac remodelling. Nevertheless, there is a possibility that combining them in clinical practice may prove more beneficial than using either one of them separately. Whether the use of ACE-I in our system in combination with candesartan will have any effect, additive or synergistic, remains to be determined.
Conclusion
Candesartan abrogates the hypertrophic response in neonatal rat cardiomyocytes exposed to ET-1 and PE, along with Ang II. Our data suggest that inactivation of the MAP kinase signalling pathways by candesartan may underlie its antihypertrophic effects. From a clinical standpoint, this is an extremely important point, since by abrogating intracellular responses to hormonal stimuli that are known to be toxic to the myocardium, candesartan may have wide ranging beneficial effects in patients with cardiac hypertrophy and left ventricular dysfunction. 
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